{"id":"NCT02637856","sponsor":"Genentech, Inc.","briefTitle":"A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)","officialTitle":"An Open-Label Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients With Relapsing Remitting Multiple Sclerosis Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-02-11","primaryCompletion":"2019-05-03","completion":"2019-05-03","firstPosted":"2015-12-22","resultsPosted":"2020-05-26","lastUpdate":"2020-05-26"},"enrollment":608,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Multiple Sclerosis, Relapsing-Remitting"],"interventions":[{"type":"DRUG","name":"Ocrelizumab","otherNames":["RO4964913"]},{"type":"DRUG","name":"Ocrelizumab","otherNames":["RO4964913"]}],"arms":[{"label":"Ocrelizumab","type":"EXPERIMENTAL"},{"label":"Ocrelizumab (substudy)","type":"EXPERIMENTAL"}],"summary":"This study will evaluate the efficacy and safety of ocrelizumab in participants with RRMS who have had a suboptimal response to an adequate course of DMT. Participants will receive ocrelizumab as an initial dose of two 300-milligrams (mg) intravenous (IV) infusions (600 mg total) separated by 14 days followed by one 600-mg IV infusion for a maximum of 4 doses (up to 96 weeks). Anticipated time on study treatment is 96 weeks.","primaryOutcome":{"measure":"Percentage of Participants Without Any Protocol-Defined Events During 96-Week Period","timeFrame":"Baseline up to Week 96","effectByArm":[{"arm":"Ocrelizumab","deltaMin":48.1,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":18},"locations":{"siteCount":82,"countries":["United States","Canada"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":47,"n":608},"commonTop":["Infusion related reaction","Urinary tract infection","Nasopharyngitis","Fatigue","Upper respiratory tract infection"]}}